Payment Breakdown by Category
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $8,772 | 9 | 81.2% |
| Unspecified | $975.00 | 1 | 9.0% |
| Travel and Lodging | $822.02 | 3 | 7.6% |
| Food and Beverage | $240.23 | 5 | 2.2% |
Payments by Type
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| GENZYME CORPORATION | $6,126 | 8 | $0 (2018) |
| Regeneron Pharmaceuticals, Inc. | $3,708 | 9 | $0 (2024) |
| Theravance Biopharma, Inc. | $975.00 | 1 | $0 (2018) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $3,648 | 8 | Regeneron Pharmaceuticals, Inc. ($3,648) |
| 2023 | $60.25 | 1 | Regeneron Pharmaceuticals, Inc. ($60.25) |
| 2018 | $7,101 | 9 | GENZYME CORPORATION ($6,126) |
All Payment Transactions
18 individual payment records from CMS Open Payments
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 05/24/2024 | Regeneron Pharmaceuticals, Inc. | DUPIXENT (Biological) | Consulting Fee | Cash or cash equivalent | $912.00 | General |
| Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 05/24/2024 | Regeneron Pharmaceuticals, Inc. | DUPIXENT (Biological) | Consulting Fee | Cash or cash equivalent | $912.00 | General |
| Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 05/24/2024 | Regeneron Pharmaceuticals, Inc. | DUPIXENT (Biological) | Consulting Fee | Cash or cash equivalent | $456.00 | General |
| Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 05/24/2024 | Regeneron Pharmaceuticals, Inc. | DUPIXENT (Biological) | Consulting Fee | Cash or cash equivalent | $456.00 | General |
| Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 05/24/2024 | Regeneron Pharmaceuticals, Inc. | DUPIXENT (Biological) | Consulting Fee | Cash or cash equivalent | $342.00 | General |
| Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 05/24/2024 | Regeneron Pharmaceuticals, Inc. | DUPIXENT (Biological) | Consulting Fee | Cash or cash equivalent | $228.00 | General |
| Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 05/24/2024 | Regeneron Pharmaceuticals, Inc. | DUPIXENT (Biological) | Consulting Fee | Cash or cash equivalent | $228.00 | General |
| Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 05/24/2024 | Regeneron Pharmaceuticals, Inc. | DUPIXENT (Biological) | Consulting Fee | Cash or cash equivalent | $114.00 | General |
| Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 04/24/2023 | Regeneron Pharmaceuticals, Inc. | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $60.25 | General |
| Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 11/01/2018 | Theravance Biopharma, Inc. | VIBATIV (Drug) | — | Cash or cash equivalent | $975.00 | Research |
| Study: Protocol #0112 A Phase 3 Multicenter, Randomized, Open-label, Clinical Trial of Telavancin Versus Standard Intravenous Therapy • Category: Infectious Disease | ||||||
| 08/16/2018 | GENZYME CORPORATION | NO PRODUCT DISCUSSED (Drug) | Consulting Fee | Cash or cash equivalent | $5,124.00 | General |
| 08/16/2018 | GENZYME CORPORATION | NO PRODUCT DISCUSSED (Drug) | Travel and Lodging | In-kind items and services | $442.17 | General |
| 08/16/2018 | GENZYME CORPORATION | NO PRODUCT DISCUSSED (Drug) | Travel and Lodging | In-kind items and services | $212.60 | General |
| 08/16/2018 | GENZYME CORPORATION | NO PRODUCT DISCUSSED (Drug) | Travel and Lodging | In-kind items and services | $167.25 | General |
| 08/16/2018 | GENZYME CORPORATION | NO PRODUCT DISCUSSED (Drug) | Food and Beverage | In-kind items and services | $57.27 | General |
| 08/16/2018 | GENZYME CORPORATION | NO PRODUCT DISCUSSED (Drug) | Food and Beverage | In-kind items and services | $40.91 | General |
| 08/16/2018 | GENZYME CORPORATION | NO PRODUCT DISCUSSED (Drug) | Food and Beverage | In-kind items and services | $40.90 | General |
| 08/16/2018 | GENZYME CORPORATION | NO PRODUCT DISCUSSED (Drug) | Food and Beverage | In-kind items and services | $40.90 | General |
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| Protocol #0112 A Phase 3 Multicenter, Randomized, Open-label, Clinical Trial of Telavancin Versus Standard Intravenous Therapy | Theravance Biopharma, Inc. | $975.00 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2020 | 3 | 69 | 70 | $61,746 | $8,030 |
All Medicare Procedures & Services
3 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99285 | Emergency department visit, problem with significant threat to life or function | Facility | 2020 | 37 | 37 | $44,807 | $5,934 | 13.2% |
| 99284 | Emergency department visit, problem of high severity | Facility | 2020 | 20 | 20 | $16,120 | $1,994 | 12.4% |
| 93010 | Routine electrocardiogram (ekg) using at least 12 leads with interpretation and report | Facility | 2020 | 12 | 13 | $819.00 | $102.96 | 12.6% |
About Robert Silverman
Robert Silverman is a Emergency Medicine healthcare provider based in New Hyde Park, New York. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 03/13/2007. The National Provider Identifier (NPI) number assigned to this provider is 1013040906.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Robert Silverman has received a total of $10,809 in payments from pharmaceutical and medical device companies, with $3,648 received in 2024. These payments were reported across 18 transactions from 3 companies. The most common payment nature is "Consulting Fee" ($8,772).
As a Medicare-enrolled provider, Silverman has provided services to 69 Medicare beneficiaries, totaling 70 services with total Medicare billing of $8,030. Data is available for 1 year (2020–2020), covering 3 distinct procedure/service records.
Practice Information
- Specialty Emergency Medicine
- Location New Hyde Park, NY
- Active Since 03/13/2007
- Last Updated 12/22/2009
- Taxonomy Code 207P00000X
- Entity Type Individual
- NPI Number 1013040906
Products in Payments
- NO PRODUCT DISCUSSED (Drug) $6,126
- DUPIXENT (Biological) $3,708
- VIBATIV (Drug) $975.00
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Emergency Medicine Doctors in New Hyde Park
Dr. Eugene Vortsman, D.o, D.O
Emergency Medicine — Payments: $5,263
Dr. Christopher Perry, M.d, M.D
Emergency Medicine — Payments: $1,163
Dr. Deven Unadkat, Do, DO
Emergency Medicine — Payments: $1,142
Dr. Ashish Kumar
Emergency Medicine — Payments: $473.15
Dr. Mark Richman, Md Mph, MD MPH
Emergency Medicine — Payments: $436.35
Joseph Frankel
Emergency Medicine — Payments: $327.04